Amar Deep Sharma

FibroRNA i.G. Globally 2 million deaths are reported annually caused by liver fibrosis. Until recently, liver transplantation was the only curative option for these patients, hampered by the scarcity of available donor livers. We at FibroRNA, aim to develop a i.v. fixed dose of miRNA for effective and safe treatment of liver fibrosis, regardless of etiology and disease stage. A one-time treatment is envisaged. This will be the first antifibrotic therapeutic, that directly targets the fibrosis causing myofibroblasts (First-in-Class approach); it can be administered in all liver fibrosis patients. A permanent antifibrotic treatment effect is expected due to sustained suppression of myofibroblast-driven fibrogenesis. The therapeutic will be developed by FibroRNA until Proof-of-Concept in a Phase II Study.